Patient Access

December 21, 2021 Alnylam Publishes 2021 Patient Access Philosophy Report Alnylam has published its 2021 Patient Access Philosophy Report detailing its actions as a company to provide access to its medicines for those who may... Read More ›
March 11, 2021 Alnylam Publishes First Corporate Responsibility Summary Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend... Read More ›
December 7, 2020 Alnylam Publishes Its 1st-Ever Rare Disease Trend Report Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
October 1, 2020 A New European Biotech Social Pact The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and... Read More ›
September 2, 2020 With Innovation in Market Access, European Patients Can Fully Experience Biotech’s Transfo ... What’s needed is a larger measure of creativity, flexibility and coordination around market access. This must become the new baseline environment in which... Read More ›
December 12, 2019 Building Bridges to Support Patients’ Care Supporting patients and their caregivers by facilitating access to innovative treatments is at the core of our Patient Access Philosophy. Read More ›
September 9, 2019 Alnylam's Patient Access Philosophy - Our Progress Nearly two years ago – before we launched our first product – we made a commitment to strive toward broad patient access to our medicines. In our view... Read More ›
Subscribe to Patient Access